FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma
Written by
American Journal Managed Care
Published
0
comments
0
min
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.